Phaseline

Companies › Tavo Biotherapeutics

Tavo Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TB0001 ophthalmic solution 0.9%
GABA analog; voltage-gated calcium channel modulator
Ion channelsPhase 2Primary Open - Angle Glaucoma (POAG)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07913074TB0001 ophthalmic solution 0.9%Phase 2Primary Open - Angle Glaucoma (POAG)OphthalmologyJun 2027
NCT07913074TB0001 ophthalmic solution 0.9%Phase 2Primary Open - Angle Glaucoma (POAG)OphthalmologyJun 2027
NCT07913074TB0001 ophthalmic solution 0.9%Phase 2Primary Open - Angle Glaucoma (POAG)OphthalmologyJun 2027

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.